Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

Rabu, 11 November 2026 - 21:29:43 Wib
Globenewswire

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

Selasa, 03 November 2026 - 23:55:19 Wib
Globenewswire

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

Senin, 02 November 2026 - 20:59:19 Wib
Globenewswire

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Selasa, 27 Oktober 2026 - 21:20:35 Wib
Globenewswire

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

Selasa, 20 Oktober 2026 - 22:12:48 Wib
Globenewswire

Teva to Host R&D Day on Wednesday, November 11 in New York City

Selasa, 13 Oktober 2026 - 06:29:48 Wib
Globenewswire

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Jumat, 09 Oktober 2026 - 22:45:09 Wib
Globenewswire

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Jumat, 02 Oktober 2026 - 21:27:28 Wib
Globenewswire

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Jumat, 02 Oktober 2026 - 21:26:38 Wib
Globenewswire

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Kamis, 01 Oktober 2026 - 22:51:45 Wib
Globenewswire

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Selasa, 29 September 2026 - 22:34:15 Wib
Globenewswire

Teva Releases Q3 2026 Aide Memoire

Kamis, 24 September 2026 - 22:18:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Kamis, 24 September 2026 - 22:17:25 Wib
Globenewswire

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Senin, 21 September 2026 - 20:24:09 Wib
Globenewswire

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Senin, 21 September 2026 - 20:23:18 Wib
Globenewswire

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Senin, 21 September 2026 - 20:22:15 Wib
Globenewswire

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

Rabu, 16 September 2026 - 22:54:54 Wib
Globenewswire

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Senin, 14 September 2026 - 21:28:13 Wib
Globenewswire

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Kamis, 10 September 2026 - 22:48:27 Wib
Globenewswire

Teva Announces Launch of Offering of Senior Notes

Senin, 07 September 2026 - 23:13:42 Wib
Globenewswire

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Jumat, 04 September 2026 - 22:48:00 Wib
Globenewswire

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Rabu, 02 September 2026 - 21:48:55 Wib
Globenewswire

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

Rabu, 02 September 2026 - 21:39:07 Wib
Globenewswire

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Selasa, 01 September 2026 - 22:16:20 Wib
Globenewswire

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

Ahad, 30 Agustus 2026 - 20:13:14 Wib